Peter Parker: Publications

  • Claus, J; Patel, G; Autore, F; Colomba, A; Weitsman, G; Soliman, TN; Roberts, S; Zanetti-Domingues, LC; Hirsch, M; Collu, F; George, R; Ortiz-Zapater, E; Barber, PR; Vojnovic, B; Yarden, Y; Martin-Fernandez, ML; Cameron, A; Fraternali, F; Ng, T and Parker, PJ (2018)
    Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.
    eLife 7, e32271 PubMed abstract
  • Francois, AA; Obasanjo-Blackshire, K; Clark, JE; Boguslavskyi, A; Holt, MR; Parker, PJ; Marber, MS and Heads, RJ (2018)
    Loss of Protein Kinase Novel 1 (PKN1) is associated with mild systolic and diastolic contractile dysfunction, increased phospholamban Thr17 phosphorylation, and exacerbated ischaemia-reperfusion injury.
    Cardiovascular Research 114, 138-157 PubMed abstract
  • Martini, S; Soliman, T; Gobbi, G; Mirandola, P; Carubbi, C; Masselli, E; Pozzi, G; Parker, PJ and Vitale, M (2018)
    PKCε controls mitotic progression by regulating centrosome migration and mitotic spindle assembly.
    Molecular Cancer Research 16, 3-15 PubMed abstract
  • Nedden, Sz; Eith, R; Schwarzer, C; Zanetti, L; Seitter, H; Fresser, F; Koschak, A; Cameron, AJM; Parker, PJ; Baier, G and Baier-Bitterlich, G (2018)
    Protein kinase N1 critically regulates cerebellar development and long-term function.
    Journal of Clinical Investigation 128, 2076-2088 PubMed abstract
  • Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE and Bliss, JM (2018)
    Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Nature Medicine [Epub ahead of print] PubMed abstract
  • Cameron, AJM; Veeriah, S; Marshall, JJT; Murray, ER; Larijani, B and Parker, PJ (2017)
    Uncoupling TORC2 from AGC kinases inhibits tumour growth.
    Oncotarget 8, 84685-84696 PubMed abstract
  • Ferreli, C; Lai, C; August, S; Buggy, Y; Kumar, P; Brownlow, N; Parker, P; Friedmann, PS; Ardern-Jones, M; Pickard, C and Healy, E (2017)
    STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin- and mucosa-derived cell types: implications in neoplastic and inflammatory skin diseases.
    Journal of the European Academy of Dermatology and Venereology 31, 1663-1673 PubMed abstract
  • Lawler, K; Papouli, E; Naceur-Lombardelli, C; Mera, A; Ougham, K; Tutt, A; Kimbung, S; Hedenfalk, I; Zhan, J; Zhang, H; Buus, R; Dowsett, M; Ng, T; Pinder, SE; Parker, P; Holmberg, L; Gillett, CE; Grigoriadis, A and Purushotham, A (2017)
    Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.
    Breast Cancer Research 19, 113 PubMed abstract
  • Miles, J; Applebee, CJ; Leboucher, P; Lopez-Fernandez, S; Lee, DJ; Guarch, R; Ward, S; Parker, PJ; López, JI and Larijani, B (2017)
    Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma.
    BBA Clinical 8, 97-102 PubMed abstract
  • Needham, SR; Zanetti-Domigues, LC; Arkhipov, A; Mysore, VP; Korovesis, D; Roberts, SK; Tynan, CJ; Rolfe, DJ; Hirsch, M; Lajevardipour, A; Clayton, AHA; Parker, PJ; Shan, YB; Shaw, DE and Martin-Fernandez, ML (2017)
    Oligomerization of the epidermal growth factor receptor organizes kinase-active dimers into competent signaling platforms.
    Biophysical Journal 112, 26A-27A, Abstract no.138-Plat
  • Ortiz-Zapater, E; Lee, RW; Owen, W; Weitsman, G; Fruhwirth, G; Dunn, RG; Neat, MJ; McCaughan, F; Parker, P; Ng, T and Santis, G (2017)
    MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mutations and altered by MET kinase inhibition.
    PLOS ONE 12, e0170798 PubMed abstract
  • Tutt, A; Cheang, MCU; Kilburn, L; Tovey, H; Gillett, C; Pinder, S; Lanchbury, J; Abraham, J; Barrett, S; Barrett-Lee, P; Chan, S; Gazinska, P; Grigoriadis, A; Kernaghan, S; Hoadley, K; Gutin, A; Harper-Wynne, C; Hatton, M; Owen, J; Parker, P; Roylance, R; Shaw, A; Smith, I; Thompson, R; Timms, K; Wardley, A; Wilson, G; Harries, M; Ellis, P; Ashworth, A; Perou, C; Bliss, J; Rahman, N; Brown, R and T. N. T. Trial Management Group and Investigators (2017)
    BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).
    Cancer Research 77, S6-01
  • Barrow-McGee, R; Kishi, N; Joffre, C; Ménard, L; Hervieu, A; Bakhouche, BA; Noval, AJ; Mai, A; Guzmán, C; Robbez-Masson, L; Iturrioz, X; Hulit, J; Brennan, CH; Hart, IR; Parker, PJ; Ivaska, J and Kermorgant, S (2016)
    Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.
    Nature Communications 7, 11942 PubMed abstract
  • Francois, AA; Clark, JE; Parker, PJ; Marber, MS and Heads, RJ (2016)
    Kinase independent cardioprotection by protein kinase novel 1 (PKN1) and SR remodelling.
    Heart 102, A15, Abstract no. P42
  • Janssens, V; Zwaenepoel, K; Rossé, C; Petit, MMR; Goris, J and Parker, PJ (2016)
    PP2A binds the LIM domains of lipoma-preferred partner through its PR130/B" subunit to regulate cell adhesion and migration.
    Journal of Cell Science 129, 1605-1618 PubMed abstract
  • McCann, J; Leonard, B; Starrett, G; Kosyakovsky, L; Molan, A; Burns, M; McDougle, R; Parker, P; Brown, W and Harris, R (2016)
    APOBEC3B upregulation by the PKC-NFκB pathway in breast cancer.
    Cancer Research 76, Abstract no.P4-08-02
  • Needham, SR; Roberts, SK; Arkhipov, A; Mysore, VP; Tynan, CJ; Zanetti-Domingues, LC; Kim, ET; Losasso, V; Korovesis, D; Hirsch, M; Rolfe, DJ; Clarke, DT; Winn, MD; Lajevardipour, A; Clayton, AHA; Pike, LJ; Perani, M; Parker, PJ; Shan, Y; Shaw, DE and Martin-Fernandez, ML (2016)
    EGFR oligomerization organizes kinase-active dimers into competent signalling platforms.
    Nature Communications 7, 13307 PubMed abstract
  • Pike, T; Brownlow, N; Kjaer, S; Carlton, J and Parker, PJ (2016)
    PKCε switches Aurora B specificity to exit the abscission checkpoint.
    Nature Communications 7, 13853 PubMed abstract
  • Quétier, I; Marshall, JJT; Spencer-Dene, B; Lachmann, S; Casamassima, A; Franco, C; Escuin, S; Worrall, JT; Baskaran, P; Rajeeve, V; Howell, M; Copp, AJ; Stamp, G; Rosewell, I; Cutillas, P; Gerhardt, H; Parker, PJ and Cameron, AJM (2016)
    Knockout of the PKN family of Rho effector kinases reveals a non-redundant role for PKN2 in developmental mesoderm expansion.
    Cell Reports 14, 440-448 PubMed abstract
  • Raimondi, C; Calleja, V; Ferro, R; Fantin, A; Riley, AM; Potter, BVL; Brennan, CH; Maffucci, T; Larijani, B and Falasca, M (2016)
    A small molecule inhibitor of PDK1/PLCγ1 interaction blocks breast and melanoma cancer cell invasion.
    Scientific Reports 6, 26142 PubMed abstract
  • Soriano, EV; Ivanova, ME; Fletcher, G; Riou, P; Knowles, PP; Barnouin, K; Purkiss, A; Kostelecky, B; Saiu, P; Linch, M; Elbediwy, A; Kjær, S; O'Reilly, N; Snijders, AP; Parker, PJ; Thompson, BJ and McDonald, NQ (2016)
    aPKC inhibition by Par3 CR3 flanking regions controls substrate access and underpins apical-junctional polarization.
    Developmental Cell 38, 384-398 PubMed abstract
  • Coban, O; Zanetti-Dominguez, LC; Matthews, DR; Rolfe, DJ; Weitsman, G; Barber, PR; Barbeau, J; Devauges, V; Kampmeier, F; Winn, M; Vojnovic, B; Parker, PJ; Lidke, KA; Lidke, DS; Ameer-Beg, SM; Martin-Fernandez, ML and Ng, T (2015)
    Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.
    Biophysical Journal 108, 1013-1026 PubMed abstract
  • Dombernowsky, SL; Samsøe-Petersen, J; Petersen, CH; Instrell, R; Hedegaard, A-MB; Thomas, L; Atkins, KM; Auclair, S; Albrechtsen, R; Mygind, KJ; Fröhlich, C; Howell, M; Parker, P; Thomas, G and Kveiborg, M (2015)
    The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17.
    Nature Communications 6, 7518 PubMed abstract
  • Jethwa, N; Chung, GHC; Lete, MG; Alonso, A; Byrne, RD; Calleja, V and Larijani, B (2015)
    Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway.
    Journal of Cell Science 128, 3456-3465 PubMed abstract
  • Larijani, B; Perani, M; Alburai'si, K and Parker, PJ (2015)
    Functional proteomic biomarkers in cancer.
    Annals of the New York Academy of Sciences 1346, 1-6 PubMed abstract
  • Leonard, B; McCann, JL; Starrett, GJ; Kosyakovsky, L; Luengas, EM; Molan, AM; Burns, MB; McDougle, RM; Parker, PJ; Brown, WL and Harris, RS (2015)
    The PKC-NFκB signaling pathway induces APOBEC3B expression in multiple human cancers.
    Cancer Research 75, 4538-4547 PubMed abstract
  • Roffey, J; Turnbull, A; Dillon, C; Boyd, S; Riou, P; Linch, M; Parker, P; Kjaer, S and McDonald, N (2015)
    Kinase identification of proximal substrates (KIPS): A novel chemical genetics approach for kinase substrate identification.
    Cancer Research 75, Abstract LB-052
  • Tutt, A; Ellis, P; Kilburn, L; Gilett, C; Pinder, S; Abraham, J; Barrett, S; Barrett-Lee, P; Chan, S; Cheang, M; Dowsett, M; Fox, L; Gazinska, P; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, M; Kernaghan, S; Lanchbury, J; Morden, J; Owen, J; Parikh, J; Parker, P; Rahman, N; Roylance, R; Shaw, A; Smith, I; Thompson, R; Timms, K; Tovey, H; Wardley, A; Wilson, G; Harries, M and Bliss, J (2015)
    The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).
    Cancer Research 75, S3-01
  • Brownlow, N; Pike, T; Crossland, V; Claus, J and Parker, P (2014)
    Regulation of the cytokinesis cleavage furrow by PKCε.
    Biochemical Society Transactions 42, 1534-1537 PubMed abstract
  • Brownlow, N; Pike, T; Zicha, D; Collinson, L and Parker, PJ (2014)
    Mitotic catenation is monitored and resolved by a PKCε-regulated pathway.
    Nature Communications 5, 5685 PubMed abstract
  • Calleja, V; Laguerre, M; de Las Heras-Martinez, G; Parker, PJ; Requejo-Isidro, J and Larijani, B (2014)
    Acute regulation of PDK1 by a complex interplay of molecular switches.
    Biochemical Society Transactions 42, 1435-1440 PubMed abstract
  • Claus, J; Patel, G; Ng, T and Parker, PJ (2014)
    A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
    Biochemical Society Transactions 42, 831-836 PubMed abstract
  • Endesfelder, D; Burrell, RA; Kanu, N; McGranahan, N; Howell, M; Parker, PJ; Downward, J; Swanton, C and Kschischo, M (2014)
    Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.
    Cancer Research 74, 4853-4863 PubMed abstract
  • Gatliff, J; East, D; Crosby, J; Abeti, R; Harvey, R; Craigen, W; Parker, P and Campanella, M (2014)
    TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control.
    Autophagy 10, 2279-2296 PubMed abstract
  • Kiuchi, T; Ortiz-Zapater, E; Monypenny, J; Matthews, DR; Nguyen, LK; Barbeau, J; Coban, O; Lawler, K; Burford, B; Rolfe, DJ; de Rinaldis, E; Dafou, D; Simpson, MA; Woodman, N; Pinder, S; Gillett, CE; Devauges, V; Poland, SP; Fruhwirth, G; Marra, P; Boersma, YL; Pluckthun, A; Gullick, WJ; Yarden, Y; Santis, G; Winn, M; Kholodenko, BN; Martin-Fernandez, ML; Parker, P; Tutt, A; Ameer-Beg, SM and Ng, T (2014)
    The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
    Science Signaling 7, ra78 PubMed abstract
  • Linch, M; Riou, P; Claus, J; Cameron, AJ; de Naurois, J; Larijani, B; Ng, T; McDonald, NQ and Parker, PJ (2014)
    Functional implications of assigned, assumed and assembled PKC structures.
    Biochemical Society Transactions 42, 35-41 PubMed abstract
  • Linch, M; Sanz-Garcia, M; Rosse, C; Riou, P; Peel, N; Madsen, CD; Sahai, E; Downward, J; Khwaja, A; Dillon, C; Roffey, J; Cameron, AJM and Parker, PJ (2014)
    Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.
    Carcinogenesis 35, 396-406 PubMed abstract
  • Martin-Liberal, J; Cameron, AJ; Claus, J; Judson, IR; Parker, PJ and Linch, M (2014)
    Targeting protein kinase C in sarcoma.
    Biochimica et Biophysica Acta 1846, 547-559 PubMed abstract
  • Ménard, L; Parker, PJ and Kermorgant, S (2014)
    Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways.
    Nature Communications 5, 3907 PubMed abstract
  • Parker, PJ; Justilien, V; Riou, P; Linch, M and Fields, AP (2014)
    Atypical protein kinase Cι as a human oncogene and therapeutic target.
    Biochemical Pharmacology 88, 1-11 PubMed abstract
  • Rossé, C; Lodillinsky, C; Fuhrmann, L; Nourieh, M; Monteiro, P; Irondelle, M; Lagoutte, E; Vacher, S; Waharte, F; Paul-Gilloteaux, P; Romao, M; Sengmanivong, L; Linch, M; van Lint, J; Raposo, G; Vincent-Salomon, A; Bièche, I; Parker, PJ and Chavrier, P (2014)
    Control of MT1-MMP transport by atypical PKC during breast-cancer progression.
    Proceedings of the National Academy of Sciences of the United States of America 111, E1872-E1879 PubMed abstract
  • Soudy, C; Stanway, E; Patel, B; Barton, C; Barnard, M; Pang, L; Owen, P; Turnbull, A; Ruggeri, BA; Dorsey, BD; Ator, MA; Ott, GR; Linch, M; Riou, P; Parker, PJ; Kjaer, S; Dillon, C; McDonald, NQ and Roffey, J (2014)
    Identification and characterization of small molecule thieno [3,2-d] pyrimidine inhibitors of Protein Kinase C iota (PKCι).
    Cancer Research 74, Abstract LB-99
  • Veeriah, S; Leboucher, P; de Naurois, J; Jethwa, N; Nye, E; Bunting, T; Stone, R; Stamp, G; Calleja, V; Jeffrey, SS; Parker, PJ and Larijani, B (2014)
    High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer.
    Cancer Research 74, 4983-4995 PubMed abstract
  • Claus, J; Cameron, AJM and Parker, PJ (2013)
    Pseudokinase drug intervention: a potentially poisoned chalice.
    Biochemical Society Transactions 41, 1083-1088 PubMed abstract
  • Kjær, S; Linch, M; Purkiss, A; Kostelecky, B; Knowles, PP; Rosse, C; Riou, P; Soudy, C; Kaye, S; Patel, B; Soriano, E; Murray-Rust, J; Barton, C; Dillon, C; Roffey, J; Parker, PJ and McDonald, NQ (2013)
    Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes.
    Biochemical Journal 451, 329-342 PubMed abstract
  • Linch, M; Sanz-Garcia, M; Soriano, E; Zhang, Y; Riou, P; Rosse, C; Cameron, A; Knowles, P; Purkiss, A; Kjaer, S; McDonald, NQ and Parker, PJ (2013)
    A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif.
    Science Signaling 6, ra82 PubMed abstract
  • Peel, N; Larijani, B and Parker, PJ (2013)
    Localised interventions in cellular processes.
    Biochimica et Biophysica Acta 1834, 1364-1370 PubMed abstract
  • Radtke, S; Milanovic, M; Rossé, C; De Rycker, M; Lachmann, S; Hibbert, A; Kermorgant, S and Parker, PJ (2013)
    ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
    Journal of Cell Science 126, 2381-2391 PubMed abstract
  • Riou, P; Kjær, S; Garg, R; Purkiss, A; George, R; Cain, RJ; Bineva, G; Reymond, N; McColl, B; Thompson, AJ; O'Reilly, N; McDonald, NQ; Parker, PJ and Ridley, AJ (2013)
    14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins.
    Cell 153, 640-653 PubMed abstract
  • Milanovic, M; Radtke, S; Peel, N; Howell, M; Carrière, V; Joffre, C; Kermorgant, S and Parker, PJ (2012)
    Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid.
    International Journal of Cancer 130, 1060-1070 PubMed abstract
  • Rosse, C; Boeckeler, K; Linch, M; Radtke, S; Frith, D; Barnouin, K; Morsi, AS; Hafezparast, M; Howell, M and Parker, PJ (2012)
    Binding of dynein intermediate chain 2 to paxillin controls focal adhesion dynamics and migration.
    Journal of Cell Science 125, 3733-3738 PubMed abstract
  • Cameron, AJM; Linch, MD; Saurin, AT; Escribano, C and Parker, PJ (2011)
    mTORC2 targets AGC kinases through Sin1-dependent recruitment.
    Biochemical Journal 439, 287-297 PubMed abstract
  • Carlin, LM; Evans, R; Milewicz, H; Fernandes, L; Matthews, DR; Perani, M; Levitt, J; Keppler, MD; Monypenny, J; Coolen, T; Barber, PR; Vojnovic, B; Suhling, K; Fraternali, F; Ameer-Beg, S; Parker, PJ; Thomas, NSB and Ng, T (2011)
    A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse.
    Science Signaling 4, ra81 PubMed abstract
  • Collazos, A; Michael, N; Whelan, RDH; Kelly, G; Mellor, H; Pang, LCH; Totty, N and Parker, PJ (2011)
    Site recognition and substrate screens for PKN family proteins.
    Biochemical Journal 438, 535-543 PubMed abstract
  • Kveiborg, M; Instrell, R; Rowlands, C; Howell, M and Parker, PJ (2011)
    PKCα and PKCδ regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways.
    PLOS ONE 6, e17168 PubMed abstract
  • Lachmann, S; Jevons, A; De Rycker, M; Casamassima, A; Radtke, S; Collazos, A and Parker, PJ (2011)
    Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration.
    PLOS ONE 6, e21732 PubMed abstract
  • Salehi-Reyhani, A; Kaplinsky, J; Burgin, E; Novakova, M; deMello, AJ; Templer, RH; Parker, P; Neil, MAA; Ces, O; French, P; Willison, KR and Klug, D (2011)
    A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection.
    Lab on a Chip 11, 1256-1261 PubMed abstract
  • Tynan, CJ; Roberts, SK; Rolfe, DJ; Clarke, DT; Loeffler, HH; Kästner, J; Winn, MD; Parker, PJ and Martin-Fernandez, ML (2011)
    Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry.
    Molecular and Cellular Biology 31, 2241-2252 PubMed abstract
  • Verma, SK; Ganesan, TS; Kishore, U and Parker, PJ (2011)
    The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A.
    Protein & Cell 2, 237-249 PubMed abstract
  • Boeckeler, K; Rosse, C; Howell, M and Parker, PJ (2010)
    Manipulating signal delivery - plasma-membrane ERK activation in aPKC-dependent migration.
    Journal of Cell Science 123, 2725-2732 PubMed abstract
  • Cameron, AJM and Parker, PJ (2010)
    Protein kinase C - a family of protein kinases, allosteric effectors or both?
    Advances in Enzyme Regulation 50, 169-177 PubMed abstract
  • Chen, W-Q; Graf, C; Zimmel, D; Rovina, P; Krapfenbauer, K; Jaritz, M; Parker, PJ; Lubec, G and Bornancin, F (2010)
    Ceramide kinase profiling by mass spectrometry reveals a conserved phosphorylation pattern downstream of the catalytic site.
    Journal of Proteome Research 9, 420-429 PubMed abstract
  • Durgan, J and Parker, PJ (2010)
    Regulation of the tumour suppressor Fbw7α by PKC-dependent phosphorylation and cancer-associated mutations.
    Biochemical Journal 432, 77-87 PubMed abstract
  • Flinn, RJ; Yan, Y; Goswami, S; Parker, PJ and Backer, JM (2010)
    The late endosome is essential for mTORC1 signaling.
    Molecular Biology of the Cell 21, 833-841 PubMed abstract
  • Gijsen, M; King, P; Perera, T; Parker, P; Larijani, B; Harris, A and Kong, A (2010)
    Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
    Breast Cancer Research 12, O2
  • Gijsen, M; King, P; Perera, T; Parker, PJ; Harris, AL; Larijani, B and Kong, A (2010)
    HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
    PLOS Biology 8, e1000563 PubMed abstract
  • Rosse, C; Linch, M; Kermorgant, S; Cameron, AJM; Boeckeler, K and Parker, PJ (2010)
    PKC and the control of localized signal dynamics.
    Nature Reviews Molecular Cell Biology 11, 103-112 PubMed abstract
  • Zwaenepoel, K; Goris, J; Erneux, C; Parker, PJ and Janssens, V (2010)
    Protein phosphatase 2A PR130/B''α1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling.
    FASEB Journal 24, 538-547 PubMed abstract

[Page last updated 1 Jun 2018]

Peter Parker
+44 (0)20 379 61977

  • Qualifications and history
  • 1979 PhD in Biochemistry, Oxford, UK
  • 1979 MRC Postdoctoral Fellowship, Dundee, UK
  • 1982 Postdoctoral Fellow, Imperial Cancer Research Fund, UK
  • 1985 Laboratory Head, Imperial Cancer Research Fund, UK
  • 1986 Laboratory Head, Ludwig Institute for Cancer Research, UK
  • 1990 Principal Investigator at the Imperial Cancer Research Fund, UK (in 2002 the Imperial Cancer Research Fund became Cancer Research UK)
  • 2006 Head of the Division of Cancer Studies King's College London, UK
  • 2015 Group Leader, the Francis Crick Institute, London, UK